

**GORE® PRECLUDE®**  
Pericardial Membrane

# DESIGNED TO MINIMIZE TISSUE ATTACHMENT

Evidence supporting improved reoperation:  
GORE® PRECLUDE® Pericardial Membrane for  
pericardial reconstruction or repair in conjunction  
with left ventricular assist device (LVAD) and  
other circulatory device patients



*Together, improving life*



# GORE® PRECLUDE® Pericardial Membrane

Evidence supporting improved reoperation.

## EFFECTIVE

Shown to facilitate reentry during reoperation.<sup>1-14</sup>

## CONSERVES TIME

Reported to reduce reoperation time and ease explantation.<sup>2,5,6,13</sup>

## SAFE

Demonstrated to have low risk of infection.<sup>1-4, 7-9, 11-17</sup>

## 15 clinical experiences

demonstrate efficacy and safety of utilizing GORE® PRECLUDE® Pericardial Membrane to support reoperations<sup>1-5, 6-9, 12-17</sup>

## ~2,900 patients

were reported to be implanted with GORE® PRECLUDE® Pericardial Membrane, mostly to minimize tissue attachment<sup>1-18</sup>

# EFFECTIVE

According to results from clinical studies/reports utilizing GORE® PRECLUDE® Pericardial Membrane in total artificial heart (TAH) and LVAD surgeries:



# 100%

of patients were free of severe adhesion at reoperation<sup>5, 11-13, 18</sup>

**Reoperation patients implanted with an LVAD or TAH and GORE® PRECLUDE® Pericardial Membrane**

**N = 65**

Patients with severe adhesions

0 (0.0%)



**Tissue attachment is known to lead to cardiac injury and increase reoperation time.**

Image courtesy of Redo Valve Surgery Nowadays: What Have we Learned?, Acta Chirurgica Belgica, 103:5, 475-480, DOI: 0.1080/00015458.2003.11679470 Dr. Pierre Wauthy, Acta Chirurgica Belgica, © The Royal Belgian Society for Surgery, reprinted by permission of Taylor & Francis Ltd, <http://www.tandfonline.com> on behalf of The Royal Belgian Society for Surgery and Prof. Pierre Wauthy. Used with permission.

# CONSERVES TIME

Results reported from a clinical study utilizing GORE® PRECLUDE® Pericardial Membrane while implanting a TAH demonstrate:<sup>13</sup>

GORE® PRECLUDE® Pericardial Membrane can reduce reoperation time substantially.<sup>2,5,6,13</sup>



## >50%

decrease in time required to remove a TAH<sup>13</sup>

Reoperation steps	Average time without GORE® PRECLUDE® Pericardial Membrane <sup>13</sup>	Average time with GORE® PRECLUDE® Pericardial Membrane <sup>13</sup>
Removal of TAH	~2 hours	~0.5–1 hour
From incision to cannulation	84 minutes	57 minutes

“In the few patients who were reoperated, mediastinal and heart dissection was accomplished in a few minutes.”<sup>2</sup>



Yau TM, Rao V. Facilitating reoperations using GORE® PRECLUDE® Pericardial Membrane to wrap left ventricular assist devices. Presented at Optimizing reoperation in LVAD patients utilizing GORE® PRECLUDE® Pericardial Membrane. A Gore webinar series for healthcare professionals; March 4, 2021; Toronto Ontario, Canada.

# SAFE

According to published studies, LVAD and TAH implantations increase the risk of infection regardless of utilizing GORE® PRECLUDE® Pericardial Membrane during surgery.<sup>19,20</sup>

# 6.4% – 53.7%<sup>21</sup>

Meta analysis: infection rate range of LVAD and TAH surgeries



# 7.7%

clinical studies/reports utilizing GORE® PRECLUDE® Pericardial Membrane have shown an infection rate within the range associated with LVAD and TAH surgeries<sup>5, 11–13, 18</sup>

# ORDERING INFORMATION

GORE® PRECLUDE® Pericardial Membrane.

<b>Catalogue number</b>	<b>Nominal thickness (mm)</b>	<b>Nominal width (cm)</b>	<b>Nominal length (cm)</b>
1PCM100	0.1	6	12
1PCM102	0.1	12	12
1PCM103	0.1	15	20

## References

1. Mestres C-A, Comas JV, Ninot S, *et al.* The use of polyetherurethane urea (Mitrathane) and polytetrafluoroethylene (Gore-Tex) membranes for pericardial closure: initial clinical results. *Thai Journal of Surgery* 1986;7(4):125-128.
2. Minale C, Nikol S, Hollweg G, Mittermayer C, Messmer BJ. Clinical experience with expanded polytetrafluoroethylene Gore-Tex surgical membrane for pericardial closure: a study of 110 cases. *Journal of Cardiac Surgery* 1988;3(3):193-201.
3. Amato JJ, Cotroneo JV, Galdieri RJ, Alboliras E, Antillon J, Vogel RL. Experience with the polytetrafluoroethylene surgical membrane for pericardial closure in operations for congenital cardiac defects. *Journal of Thoracic & Cardiovascular Surgery* 1989;97(6):929-934.
4. Loebe M, Alexi-Meskishvili V, Weng Y, Hausdorf G, Hetzer R. Use of polytetrafluoroethylene surgical membrane as a pericardial substitute. *Texas Heart Institute Journal* 1993;20(3):213-217.
5. Holman WL, Bourge RC, Zorn GL, Brantley LH, Kirklin JK. Use of expanded polytetrafluoroethylene pericardial substitute with ventricular assist devices. *Annals of Thoracic Surgery* 1993;55(1):181-183.
6. Bacaner TJ, Young JN, DeCampi WM, Hardy C. Pericardial substitute and emergency re-sternotomy: life-saving combination. *Pediatric Cardiology* 1996;17(6):396-398.
7. Jacobs JP, Iyer RS, Weston JS, *et al.* Expanded PTFE membrane to prevent cardiac injury during re-sternotomy for congenital heart disease. *Annals of Thoracic Surgery* 1996;62(6):1778-1782.
8. Minale C, Hollweg G, Nikol S, Mittermayer CH, Messmer BJ. Closure of the pericardium using expanded polytetrafluoroethylene GORE-TEX surgical membrane: clinical experience. *Thoracic & Cardiovascular Surgeon* 1987;35(5):312-315.
9. Revuelta JM, Garcia-Rinaldi R, Johnston RH Jr, Vaughan GD 3rd. Implantation of pericardial substitutes. *Annals of Thoracic Surgery* 1985;39(2):190-191.
10. Lahtinen J, Satta J, Pokela R, Nissinen J, Juvonen T. Pericardial closure with polytetrafluoroethylene surgical membrane or biodegradable polyglycolic acid mesh after coronary artery bypass surgery—a baseline report. *Annales Chirurgiae et Gynaecologiae* 1998;87(1):36-39.
11. LePrince P, Rahmati M, Bonnet N, *et al.* Expanded polytetrafluoroethylene membranes to wrap surfaces of circulatory support devices in patients undergoing bridge to heart transplantation. *European Journal of Cardio-thoracic Surgery* 2001;19(3):302-306.
12. Vitali E, Russo C, Tiziano C, Lanfranchi M, Bruschi G. Modified pericardial closure technique in patients with ventricular assist device. *Annals of Thoracic Surgery* 2000;69(4):1278-1279.
13. Copeland JG, Arabia FA, Smith RG, Covington D. Synthetic membrane neo-pericardium facilitates total artificial heart explantation. *Journal of Heart & Lung Transplantation* 2001;20(6):654-656.
14. Bezon E, Maguid YA, Gueret G, Choplain JN, Aziz AA, Barra JA. Wrapping of the left internal thoracic artery with an expanded polytetrafluoroethylene membrane. *Annals of Thoracic Surgery* 2006;8(1):383-385.
15. Alexi-Meskishvili V, Weng Y, Uhlemann F, Lange PE, Hetzer R. Prolonged open sternotomy after pediatric open heart operation: experience with 113 patients. *Annals of Thoracic Surgery* 1995;59(2):379-383.
16. Ozeren M, Han U, Mavioglu I, *et al.* Consequences of PTFE membrane used for prevention of re-entry injuries in rheumatic valve disease. *Cardiovascular Surgery* 2002;10(5):489-493.
17. Kajiwara H, Ichikawa Y, Yamazaki I, Uranaka Y, Hamada T. Experience with expanded polytetrafluoroethylene surgical membrane (Gore-Tex surgical membrane) for coronary artery bypass grafting does Gore-Tex surgical membrane induce postoperative mediastinitis? *ASAIO Journal* 2003;49(2):155.
18. Kornberger A, Walter V, Khalil M, *et al.* Suspected involvement of EPTFE membrane in sterile intrathoracic abscess and pericardial empyema in a multi-allergic LVAD recipient: a case report. *Journal of Cardiothoracic Surgery* 2015;10(1):99.
19. Holman WL, Skinner JL, Waites KB, Benza RL, McGiffin DC, Kirklin JK. Infection during circulatory support with ventricular assist devices. *Annals of Thoracic Surgery* 1999;68(2):711-716.
20. Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist devices. *New England Journal of Medicine* 1998;339(21):1522-1533.
21. Maniar S, Kondareddy S, Topkara VK. Left ventricular assist device-related infections: past, present and future. *Expert Review of Medical Devices* 2011;8(5):627-634.

 Consult Instructions  
for Use  
[eifu.goremedical.com](http://eifu.goremedical.com)

Refer to *Instructions for Use* at [eifu.goremedical.com](http://eifu.goremedical.com) for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available.  $\text{Rx}$  Only

Products listed may not be available in all markets.

GORE, *Together, improving life*, PRECLUDE and designs are trademarks of W. L. Gore & Associates.  
© 2022, 2023 W. L. Gore & Associates GmbH 231143149-EN AUGUST 2023

---

**W. L. Gore & Associates, Inc.**  
[goremedical.com](http://goremedical.com)

**Asia Pacific** +65 67332882 **Australia/New Zealand** 1800 680 424 **Europe** 00800 6334 4673  
**United States** Flagstaff, AZ 86004 800 437 8181 928 779 2771

